Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alastair M Thompson

Showing results (111-120 of 195) with videos related to

Pageof 20
Sort By:
BMJ Open|January 8, 2022
Breast screening atypia and subsequent development of cancer: protocol for an observational analysis of the Sloane database in England (Sloane atypia cohort study)David Jenkinson, Karoline Freeman, Karen Clements, et al.
Biomarkers : Biochemical Indicators of Exposure, Response, and Susceptibility to Chemicals|January 17, 2023
Thymidine kinase activity levels in serum can identify HR+ metastatic breast cancer patients with a low risk of early progression (SWOG S0226)Mattias Bergqvist, Adrian Nordmark, Amy Williams, et al.
Breast (Edinburgh, Scotland)|January 9, 2022
Unresected screen-detected ductal carcinoma in situ: Outcomes of 311 women in the Forget-Me-Not 2 studyAnthony J Maxwell, Bridget Hilton, Karen Clements, et al.
Radiology|January 10, 2023
Surveillance Imaging after Primary Diagnosis of Ductal Carcinoma in SituDanalyn Byng, Samantha M Thomas, Christel N Rushing, et al.
NPJ Breast Cancer|May 13, 2023
Image analysis-based tumor infiltrating lymphocytes measurement predicts breast cancer pathologic complete response in SWOG S0800 neoadjuvant chemotherapy trialKristina A Fanucci, Yalai Bai, Vasiliki Pelekanou, et al.
European Journal of Radiology|April 22, 2019
Imaging features of triple-negative breast cancers according to androgen receptor statusRosalind P Candelaria, Beatriz E Adrada, Wei Wei, et al.
BMJ Open|December 19, 2022
Cohort profile of the Sloane Project: methodology for a prospective UK cohort study of >15 000 women with screen-detected non-invasive breast neoplasiaKaren Clements, David Dodwell, Bridget Hilton, et al.
Clinical Breast Cancer|August 6, 2018
Neoadjuvant Pertuzumab-containing Regimens Improve Pathologic Complete Response Rates in Stage II to III HER-2/neu-positive Breast Cancer: A Retrospective, Single Institution ExperienceRashmi K Murthy, Akshara S Raghavendra, Kenneth R Hess, et al.
Breast Cancer Research and Treatment|September 3, 2010
Comprehensive CYP2D6 genotype and adherence affect outcome in breast cancer patients treated with tamoxifen monotherapyAlastair M Thompson, Andrea Johnson, Philip Quinlan, et al.
British Journal of Cancer|October 12, 2022
The presentation, management and outcome of patients with ductal carcinoma in situ (DCIS) with microinvasion (invasion ≤1 mm in size)-results from the UK Sloane ProjectAbeer M Shaaban, Bridget Hilton, Karen Clements, et al.
Pageof 20

Showing results (111-120 of 195) with videos related to

Sort By:
Pageof 20
BMJ Open|January 8, 2022
Breast screening atypia and subsequent development of cancer: protocol for an observational analysis of the Sloane database in England (Sloane atypia cohort study)David Jenkinson, Karoline Freeman, Karen Clements, et al.
Biomarkers : Biochemical Indicators of Exposure, Response, and Susceptibility to Chemicals|January 17, 2023
Thymidine kinase activity levels in serum can identify HR+ metastatic breast cancer patients with a low risk of early progression (SWOG S0226)Mattias Bergqvist, Adrian Nordmark, Amy Williams, et al.
Breast (Edinburgh, Scotland)|January 9, 2022
Unresected screen-detected ductal carcinoma in situ: Outcomes of 311 women in the Forget-Me-Not 2 studyAnthony J Maxwell, Bridget Hilton, Karen Clements, et al.
Radiology|January 10, 2023
Surveillance Imaging after Primary Diagnosis of Ductal Carcinoma in SituDanalyn Byng, Samantha M Thomas, Christel N Rushing, et al.
NPJ Breast Cancer|May 13, 2023
Image analysis-based tumor infiltrating lymphocytes measurement predicts breast cancer pathologic complete response in SWOG S0800 neoadjuvant chemotherapy trialKristina A Fanucci, Yalai Bai, Vasiliki Pelekanou, et al.
European Journal of Radiology|April 22, 2019
Imaging features of triple-negative breast cancers according to androgen receptor statusRosalind P Candelaria, Beatriz E Adrada, Wei Wei, et al.
BMJ Open|December 19, 2022
Cohort profile of the Sloane Project: methodology for a prospective UK cohort study of >15 000 women with screen-detected non-invasive breast neoplasiaKaren Clements, David Dodwell, Bridget Hilton, et al.
Clinical Breast Cancer|August 6, 2018
Neoadjuvant Pertuzumab-containing Regimens Improve Pathologic Complete Response Rates in Stage II to III HER-2/neu-positive Breast Cancer: A Retrospective, Single Institution ExperienceRashmi K Murthy, Akshara S Raghavendra, Kenneth R Hess, et al.
Breast Cancer Research and Treatment|September 3, 2010
Comprehensive CYP2D6 genotype and adherence affect outcome in breast cancer patients treated with tamoxifen monotherapyAlastair M Thompson, Andrea Johnson, Philip Quinlan, et al.
British Journal of Cancer|October 12, 2022
The presentation, management and outcome of patients with ductal carcinoma in situ (DCIS) with microinvasion (invasion ≤1 mm in size)-results from the UK Sloane ProjectAbeer M Shaaban, Bridget Hilton, Karen Clements, et al.
Pageof 20